Davidsson et al recently found that high numbers of stromal CD4+ Tregs were identified in patients with post‐atrophic hyperplasia and prostate cancer.10 In contrast, we found a lower Treg frequency in peripheral blood from BPH patients, but Treg infiltration increased into prostatic tissue with mild or moderate inflammation, and in severely inflamed prostates, Tregs almost disappeared. The gene discussed is CD4; the disease is prostate carcinoma.